6533b86cfe1ef96bd12c81e2

RESEARCH PRODUCT

Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion

Rafaela HoltappelsAndrea FickJeanette BakerHarald WajantMatthias J. ReddehaseThomas MüllerDaniela N. MännelAndreas BrandlThorsten WinterViktoria SchäferHermann EinseleCarina A. BäuerleinAxel SeherJürgen PodlechSabrina KrausJohannes PolzEliana RibechiniTim SteinfattSven KrappmannJanina KuenJuliane KumsJorge AmichAndreas BeilhackHidekazu NishikiiKatja J. OttmüllerFriederike Berberich-siebeltAnja MottokManfred B. LutzMiriam RitzAna-laura Jordán-garroteMartin VaethKatharina MattenheimerChristian BredeStefanie SchwinnMartin ChopraMarlene Biehl

subject

0301 basic medicineInterleukin 2medicine.medical_treatmentImmunologyGraft vs Host DiseaseMice Inbred Strainschemical and pharmacologic phenomenaHematopoietic stem cell transplantationBiologyT-Lymphocytes RegulatoryArticleMice03 medical and health sciencesInterleukin 21immune system diseaseshemic and lymphatic diseasesmedicineAnimalsReceptors Tumor Necrosis Factor Type IIImmunology and AllergyCytotoxic T cellddc:610Research Articlesintegumentary systemMyeloid-Derived Suppressor CellsHematopoietic Stem Cell TransplantationFOXP3hemic and immune systemsmedicine.diseaseLeukemiaddc:57030104 developmental biologysurgical procedures operativeAcute DiseaseImmunologyMyeloid-derived Suppressor CellInterleukin-2FemaleTumor necrosis factor receptor 2medicine.drug

description

Activation of TNFR2 with a novel agonist expands T reg cells in vivo and protects allo-HCT recipients from acute GvHD while sparing antilymphoma and antiinfectious properties of transplanted donor T cells.

10.1084/jem.20151563https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/18764